Airway Therapeutics
Developing a new class of biologics for patients with respiratory and inflammatory diseases.
Developing a new class of biologics for patients with respiratory and inflammatory diseases.
Airway Therapeutics is a biotechnology startup founded in 2011 and headquartered in the United States. The company’s focus is on developing a new class of biologics for patients with respiratory and inflammatory diseases. Born as a spin-out of Cincinnati Children's Hospital Medical Center (CCHMC), Airway Therapeutics leverages extensive expertise in protein development, particularly for applications in the lungs and pediatrics. The company has made significant progress and is currently in the advanced preclinical phase of developing AT-100 (rhSP-D), a product targeting bronchopulmonary dysplasia (BPD) in newborns. Noteworthy is the fact that the company successfully secured a significant $15.50M Series C investment on 05 December 2019. The participating investors in this round included CincyTech, Queen City Angels, Cincinnati Children’s, and Danmar Capital. Airway Therapeutics’ strong foundation, strategic partnerships, and promising developments in a critical area of healthcare make it an appealing prospect for venture capitalists seeking investment opportunities in the biotechnology, healthcare, and pharmaceutical industries.
| Funding Stage | Amount | No. Investors | Investors | Date |
|---|---|---|---|---|
| Series C | $15.50M | 4 |
|
05 Dec 2019 |
| Series B | $10.93M | 3 |
|
13 Mar 2018 |
| Convertible Note | $6.40M | 3 |
|
06 Mar 2017 |
| Series A | $4.70M | 5 |
|
10 Sep 2014 |
| Angel Round | $750.00K | - | 01 Jul 2014 |
No recent news or press coverage available for Airway Therapeutics.
We care about your data, and we'd love to use cookies make your experience better.
